Generics

Dr. Reddy's is offering generic Diprivan (propofol) injectable emulsion, which had a market value of roughly $310 million for the year ended November 2018, according to IQVIA data.

Lannett is launching generic Syprine and Comtan, which had a market value of $140 million, and $23 million, respectively.

Todd Branning, formerly Teva’s CFO, has joined Amneal as senior vice president and CFO.

Slayback’s generic Makena also is the first generic of Amag Pharmaceuticals’ drug in a multidose vial.

Samsung Bioepis has received its first approval for an oncology drug from the Food and Drug Administration, which has given the green light to the company's Ontruzant — a biosimilar of Herceptin.

The drug had a market size of roughly $2.5 billion for the 12 months ended September 2018, according to IQVIA data.

Vitruvius Therapeutics has received the FDA's blessing for its vitamin B-12 injection, which had a market value of roughly $74.3 million for the year ended September 2018.

Nexus Pharmaceuticals' generic Busulfex is the company's second oncology generic drug.